Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs.
about
Confined crystallization of fenofibrate in nanoporous silica.Multi-Functional Nanogels for Tumor Targeting and Redox-Sensitive Drug and siRNA Delivery.CLSM as quantitative method to determine the size of drug crystals in a solid dispersion.Continuous production of drug nanoparticle suspensions via wet stirred media milling: a fresh look at the Rehbinder effect.Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugsSupercritical fluid technology for enhanced drug delivery.Particle size analysis in pharmaceutics: principles, methods and applications.Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.Solid dispersions, part II: new strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.CDER risk assessment exercise to evaluate potential risks from the use of nanomaterials in drug products.Recent advancements in mechanical reduction methods: particulate systems.Challenges and emerging solutions in the development of compressed orally disintegrating tablets.Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A ReviewEnhancing cisplatin delivery to hepatocellular carcinoma HepG2 cells using dual sensitive smart nanocomposite.Characterization of nano oxaliplatin prepared by novel Fat Employing Supercritical Nano System, the FESNS®.A systematic approach to design and prepare solid dispersions of poorly water-soluble drug.Nanoparticulate fingolimod delivery system based on biodegradable poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV): design, optimization, characterization and in-vitro evaluation.Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.Using USP I and USP IV for discriminating dissolution rates of nano- and microparticle-loaded pharmaceutical strip-films.Dissolution enhancement of a drug exhibiting thermal and acidic decomposition characteristics by fusion processing: a comparative study of hot melt extrusion and KinetiSol dispersing.D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension.In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line Raman spectroscopy.Monitoring ibuprofen release from multiparticulates: in situ fiber-optic technique versus the HPLC method: a technical note.A novel high-pressure precipitation tandem homogenization technology for drug nanocrystals production - a case study with ursodeoxycholic acid.The effect of homogenization method on the properties of carbamazepine microparticles prepared by spray congealing.Preparation of concentrated stable fenofibrate suspensions via liquid antisolvent precipitation.Estimation of drug solubility in polymers via differential scanning calorimetry and utilization of the fox equation.Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process.Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.Gelucire 44/14 based immediate release formulations for poorly water-soluble drugs.Experimental and molecular modeling approach to optimize suitable polymers for fabrication of stable fluticasone nanoparticles with enhanced dissolution and antimicrobial activity.Preparation, characterization, and scale-up of ketoconazole with enhanced dissolution and bioavailability.Preparation of lovastatin matrix sustained-release pellets by extrusion-spheronization combined with microcrystal dispersion technique.Preparation, characterizations and anti-pollutant activity of 7,3′,4′-trihydroxyisoflavone nanoparticles in particulate matter-induced HaCaT keratinocytes.Water in the human body: An anesthesiologist's perspective on the connection between physicochemical properties of water and physiologic relevance.
P2860
Q31037436-F2286CA8-035D-4C9D-A6C0-968D0E1F2091Q31144684-99DFD685-F0B2-4AF6-999E-CEB196910630Q33910031-7BCB825B-0E4B-4300-96FF-293B0608B950Q34232283-0738D9F7-1E9C-4FFF-AEFA-BB1CC4AF6A80Q34728884-9E65A226-298E-4921-91AA-703102D9629EQ36088451-F59C5DC4-E05A-4F54-9D9F-00FA0F243613Q36137260-9FEF55E6-6348-4C53-BAD4-8D2039E38412Q36316895-1EBFA826-5AAC-4981-A99E-FA5ED825E602Q36693368-BA90F861-409C-4F84-B887-85E0F075E147Q37565681-1736D82B-2A2C-42A2-A0CC-7F1B62F4E7BCQ37932559-2FC33EB9-8306-4E7F-BA8D-577AEA8B16FBQ37932560-E7BA6B0E-14C6-4461-B4DF-0BA317BEC063Q38091386-1EAE6347-D8C9-487D-9A7B-4580B502AEA4Q38132471-96519034-4209-4958-B527-A515FA78A4F4Q38232117-6B2DDCE0-EF85-40BE-A3C1-6D057C08FFF3Q38573948-7110340B-8FC5-418E-818B-DE58A8D29B75Q38697847-1DB6F4B3-97DE-4E94-BBA4-65B659832FC1Q39632550-63A917F0-A2A6-4174-B0FB-03EF87F657A0Q40027323-B6C17A49-D608-47DF-91FA-B659A0BA2102Q40336488-F8FA024E-AF74-455A-9ABB-426130ABB794Q40620607-5693A0B1-D79C-494E-BF58-5AB00112B6A1Q41988138-8EFC7DD1-B870-4A7C-A8B0-1B353327EC5BQ41988865-EB16CD40-124C-4B78-97DD-B178502D6BD8Q42012709-40D31FD4-1223-4182-AAB7-5BE8A21CF0A7Q42107363-4426D18C-2AC2-4373-BFF4-BB3B1E3F0033Q42374146-A6AFCA26-B075-4ACC-B39D-A0285622918CQ42563961-0F5F071C-D2BC-4C03-A561-0CBBFFC63514Q44072586-62062113-8031-4513-9BFE-A0912E06DA24Q44597484-B8521D07-EB9A-42C6-B036-AAB6EF4AC98FQ44668443-2F38249F-3DC8-4A83-9C91-6601C4209A0EQ46339838-55CFD317-42D6-413F-9BD1-B1E075E5DA36Q46437949-BA3E292A-CCB0-424C-96DC-A0921169AAC0Q46966998-9847CA63-4944-4C27-A587-0136F3DC31BDQ47900371-D6C3B445-D689-4345-864C-DC6A41CC6E80Q49157669-0CABD8BD-907E-4397-A9DA-905A53FAA651Q49957833-EBF78D1F-8F3F-4BB4-AF39-5801738615F8Q50951093-A7484F4B-C70A-4978-A3E9-9A04DFD1B51FQ53187597-04B22A5D-AB86-4C2D-9E6A-F187B70CBCCCQ55109237-B25ADB9D-2147-4D1D-99FB-EE28AD26AA9AQ55435571-80FA7CAF-7070-4B0A-AE6C-17885CBE7872
P2860
Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Nanoparticle engineering proce ...... of poorly water soluble drugs.
@ast
Nanoparticle engineering proce ...... of poorly water soluble drugs.
@en
type
label
Nanoparticle engineering proce ...... of poorly water soluble drugs.
@ast
Nanoparticle engineering proce ...... of poorly water soluble drugs.
@en
prefLabel
Nanoparticle engineering proce ...... of poorly water soluble drugs.
@ast
Nanoparticle engineering proce ...... of poorly water soluble drugs.
@en
P2093
P2860
P356
P1476
Nanoparticle engineering proce ...... of poorly water soluble drugs.
@en
P2093
Keith P Johnston
Robert O Williams
P2860
P304
P356
10.1081/DDC-120030422
P407
P577
2004-03-01T00:00:00Z